Why These Research Questions Exist
Body weight dominates headlines about metabolic research. But clinical trial programs sometimes investigate other outcomes related to the populations in which obesity occurs. Two registered eloralintide programs raise questions about obstructive sleep apnea and knee osteoarthritis pain. Their existence matters because it reveals what investigators intend to study. It does not mean either question has been answered.
The Sleep Apnea Program
ClinicalTrials.gov lists NCT07369011, acronym ENLIGHTEN-3, as a Phase 3 master protocol for adults with moderate to severe obstructive sleep apnea and obesity or overweight. [1] The sponsor is Eli Lilly and Company, and the design is randomized, double-blind and placebo-controlled. As of October 13, 2026 the record shows a status of recruiting, a planned enrollment of 800 participants, a start date of February 10, 2026 and an estimated primary completion in March 2028.
The master protocol is designed to support two independent studies. One (YSA1) is for participants who are unable or unwilling to use positive airway pressure therapy. The other (YSA2) is for participants who have used it for at least three months and plan to continue. The registered primary outcomes are percent change in body weight and change in the apnea-hypopnea index, both measured from baseline to Week 64.
Sleep apnea research can examine measures that have little in common with a simple scale reading. A properly designed trial has to specify the population and the endpoints before the results can be interpreted. The registry is where those plans belong. It is not a substitute for results reporting.
The Knee Osteoarthritis Program
ClinicalTrials.gov lists NCT07353931, acronym ENLIGHTEN-4, as a Phase 3 master protocol for adults with osteoarthritis knee pain and obesity or overweight. [2] As of October 13, 2026 the record shows a status of recruiting, a planned enrollment of 900 participants, a start date of February 9, 2026 and an estimated primary completion in March 2028. The registered primary outcomes are percent change in body weight and change in the pain subscale of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), both measured from baseline to Week 64.
Pain and movement are complicated experiences. A change in body weight, when observed in one research setting, cannot be taken as proof of a change in knee symptoms in another. That is why a separately designed program, with its own pain outcome, is scientifically relevant.
What A Master Protocol Means
A master protocol can organize related investigations under shared overarching design principles. Substudies can still involve different participant groups, interventions or outcome measures. Treating a master protocol as one interchangeable trial can obscure those distinctions.
Readers should look for the exact registered group and primary outcome before drawing conclusions about what any resulting publication might show.
Where the Evidence Stands
As of October 13, 2026, neither registry record has a posted results section, and neither lists a linked publication. A PubMed search for eloralintide on the same date returned ten records: the three primary trial reports (the first human study, the multiple-ascending-dose study and the Phase 2 trial) and seven reviews or analyses. None reports results from either of these programs.
Neither registration demonstrates a clinical benefit involving sleep apnea or knee osteoarthritis. Trial planning and clinical evidence are different milestones.
The Bottom Line
The sleep apnea and knee osteoarthritis programs show a broader research agenda. What they do not show is that eloralintide has changed those outcomes. The most interesting story will eventually be the actual measured findings, evaluated in the populations and protocols where they were obtained.
FAQ
Does a trial registration show that the compound helped sleep apnea?
No. A registered study describes a question investigators plan to test.
Is the knee program about weight alone?
No. Its registry lists two primary outcomes, percent change in body weight and change in the WOMAC pain subscale, in a population with knee osteoarthritis pain. [2]
Why are these programs separate?
The populations and research questions differ, requiring distinct study design and outcome interpretation.
Can readers infer results from the phase designation?
No. A phase designation describes development context, not efficacy or safety findings.
Further reading: Eloralintide clinical trials, Clinical development and Approval status
Editorial note
This article discusses investigational drug research for educational purposes. It does not provide medical advice, treatment recommendations, or instructions for obtaining or administering experimental compounds. Clinical findings should be interpreted within their original study populations and methodological limitations.